Aktis Oncology Stock

Aktis Oncology is a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals.

Sign up today and learn more about Aktis Oncology Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Aktis Oncology Stock

Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes.

Funding History

March 2021$72.0M
August 2022$84.0M


Co-founder and Chief Business Officer

Dr. Brian Goodman


Todd Foley

SVP, Head of CMC

Tyler Benedum


Kevin Raidy

Chief Scientific Officer

Paul Feldman


Jason Ruth


Patrick Baeuerle


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: